Oral Steroids for Acute Sciatica Produce Limited Improvement in Function and Pain

May 19, 2015, 11:00 ET from Kaiser Permanente

OAKLAND, Calif., May 19, 2015 /PRNewswire/ -- Among patients with acute sciatica caused by a herniated lumbar disk (a condition also known as "acute radiculopathy"), a short course of oral steroids resulted in only modest improvement in function and no significant improvement in pain, according to a study published today in the Journal of the American Medical Association.

Acute sciatica, characterized by radiating buttock and leg pain, is most frequently associated with a herniated disk in the lower (lumbar) spine, and occurs in more than one in 10 people sometime in their lives. Although oral steroids are used by many physicians and have been included in some clinical guidelines, no large-scale clinical trials of oral steroids for sciatica have been conducted before.

"These findings suggest that a short course of oral steroids (prednisone) is unlikely to provide much benefit for patients with sciatica due to a herniated disk in the lower back," said lead author Harley Goldberg, DO, a spine care specialist at Kaiser Permanente's San Jose Medical Center. "Despite its widespread use, we found that oral steroid treatment for acute sciatica is only modestly effective for improving function and is ineffective for reducing pain."

To determine if oral prednisone is more effective than a placebo in improving function and pain among patients with acute sciatica, the physician-researchers at the Kaiser Permanente Northern California Spine Centers and the Division of Research conducted a randomized, double-blind, placebo-controlled clinical trial from 2008 to 2013. Study participants were 269 adults with radicular pain persisting three months or less; functional impairment with a score of at least 30 on the widely used Oswestry Disability Index score (which ranges from 0-100, with higher numbers indicating greater dysfunction); and a herniated disk confirmed by magnetic resonance imaging.   

Study participants were given either a tapering 15-day course of oral prednisone or a placebo. The prednisone-treated group showed a small but greater likelihood of achieving at least a 30-point, or 50 percent, improvement in function at three weeks and at 52 weeks. However, there was no statistically significant difference between groups in changes in pain at either the three-week or 52-week time points.

"Whether the small improvement in function — without a subsequent improvement in pain — merits use of oral steroids for patients with sciatica is a difficult decision and, ultimately, becomes a personal one that must be weighed by individual patients and their care providers," noted senior author Andrew Avins, MD, MPH, a senior scientist at the Division of Research. "The value of this type of research is in providing the information necessary for physicians and their patients to have a meaningful discussion of the benefits and risks."

Acute sciatica associated with a herniated disk commonly causes substantial pain and disability and generates significant costs. Currently used treatment options include advice, education, self-care and medications (including oral steroids), followed by various physical modalities, epidural steroids and surgery (microdiskectomy) if pain persists. 

The researchers found that oral steroids did not reduce the likelihood of undergoing surgery in the year following steroid treatment. They also found no evidence for substantial improvements in other measures of quality of life. "More work is needed to identify which patients will have significant benefit from non-invasive therapies for acute radiculopathy associated with a herniated lumbar disk," noted Dr. Goldberg.

The study was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health.

Other authors of the study include William Firtch, MD, Mark Tyburski, MD, Alice Pressman, PhD, Wayne Smith, MD, Ryan Carver, MD, Annu Maratukulam, MD, and Lawrence A. Won, MD, of the Kaiser Permanente Northern California Spine Care Program; Lynn Ackerson, PhD, and Luisa Hamilton, MD, of the Kaiser Permanente Division of Research; and Eugene Carragee, MD, of the Orthopedic Spine Surgery Division, Department of Orthopedics, Stanford University.

About the Kaiser Permanente Division of Research
The Kaiser Permanente Division of Research conducts, publishes and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and society at large. It seeks to understand the determinants of illness and well-being, and to improve the quality and cost-effectiveness of health care. Currently, DOR's 500-plus staff is working on more than 400 epidemiological and health services research projects. For more information, visit www.dor.kaiser.org or follow us @KPDOR.

About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 10 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to kp.org/share.

Logo - http://photos.prnewswire.com/prnh/20130718/SF49717LOGO

SOURCE Kaiser Permanente